

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

ESPS manuscript NO: 30237

Title: Watch and wait policy in advanced neuroendocrine tumors: What does it mean?

Reviewer's code: 00699087

Reviewer's country: Japan

Science editor: Jin-Xin Kong

Date sent for review: 2016-09-23 10:36

Date reviewed: 2016-09-26 22:07

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Watch and wait policy in advanced neuroendocrine tumors: what does it mean? Fazio N. This review article discusses "Watch & wait policy" for neuroendocrine tumor, especially for advanced tumor. They concluded that this policy may be justified in good performance asymptomatic patients with low-grade neuroendocrine tumor. However, they showed serious concern to introduce this policy into patients with advanced disease. This review article is well-written with adequate references. In addition, it is very useful to understand recent reports regarding the follow up policy for neuroendocrine tumors. One point I found in this article is that they described <3% Ki-67 as definition of G1 tumor (line 4-5 of Introduction section). According to the WHO classification of tumours of the digestive system, which they referred as Reference 1, this should be $\leq 2\%$ (See p13 of this book). I think this article is very useful for many readers who participate in the treatment of patients with neuroendocrine tumors and suitable for publication in "World Journal of Clinical Oncology".

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

ESPS manuscript NO: 30237

Title: Watch and wait policy in advanced neuroendocrine tumors: What does it mean?

Reviewer's code: 00050849

Reviewer's country: Sweden

Science editor: Jin-Xin Kong

Date sent for review: 2016-09-23 10:36

Date reviewed: 2016-10-03 02:54

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

COMMENTS TO AUTHORS

This is an Editorial about "watch and wait policy in advanced NETs" by Dr Nicola Fazio who has many years of experience on NETs. The "W and W" policy is mentioned in the new guidelines of ENETS and the readers of the journal will benefit from the present Editorial by Dr N. Fazio. I have some minor suggestions: 1) At the abstract (line 2) and at the introduction (line 2) it is written that NETs may develop in "any" organ. I suggest the word "any" to be substituted by various or many. Furthermore, in introduction the grading system for G1 NETs should be changed according to the WHO reference (G1 \leq 2% Ki67 index). 2) Page 2 where the results of the Clarinet study are presented, I suggest to add a meaning that lanreotide was not effective in rectal NETs. 3) Where the good performance status I asymptomatic patients with advanced NETs is discussed I suggest that it should be made a comment why the characterization of the disease make take months rather than weeks (delay in referral to centers that focus on these tumors? Other reasons?) 4) Second last page: "Nonetheless patients..... and that this means..." please make the proper changes so that the meaning will be correct 5) Second last page, last meaning. The phrase is 5 lines long and difficult for the reader to follow. Furthermore, please change "share" to "shares". 6) Reference 1: classification.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

Please correct. 7) Reference 2: tymus. Please correct. 8) Reference 5 Wied i. Please correct the first name of the author. 9) Reference 11: Pavel Ma, O'Toole Db, Costa Fc Please correct the first names of the authors.